Video

What’s new in the NCCN’s guidelines for prostate cancer?

Author(s):

Urology Times staff

“What was published in May of 2022 was version 4 of the 2022 guidelines,” says Edward M. Schaeffer, MD, PhD.

In this video, Edward M. Schaeffer, MD, PhD, discusses the most recent updates to the National Comprehensive Cancer Network’s guidelines for prostate cancer. Schaeffer is chair and Harold Binstein Professor of Urology at Northwestern University Feinberg School of Medicine in Chicago, Illinois.

Related Videos
Raveen Syan, MD, FPMRS, answers a question during a video interview
Jaspreet S. Sandhu, MD, answers a question during a video interview
J. Quentin Clemens, MD, MSCI, answers a question during a video interview
Timothy Lyon, MD, answers a question during a video interview
Anne Pelletier Cameron, MD, FRCSC, FPMRS, answers a question during a video interview
Related Content
Standard pathology reports may be difficult to understand for patients with prostate cancer
January 23rd 2025

Standard pathology reports may be difficult to understand for patients with prostate cancer

Hannah Clarke
Overall, 39% of those who received a university-formatted report and 56% of those who received a VA-formatted report were able to identify that they had prostate cancer.
Key updates from the AUA/ASRM male infertility guideline amendment
September 23rd 2024

Key updates from the AUA/ASRM male infertility guideline amendment

Urology Times staff
In this episode, Robert E. Brannigan, MD, and Juan J. Andino, MD, MBA, discuss the recent amendment to the AUA/ASRM guideline on male infertility.
EU approves Mona Lisa 2.0 robotic system for prostate cancer
January 15th 2025

EU approves Mona Lisa 2.0 robotic system for prostate cancer

Hannah Clarke
The Mona Lisa 2.0 platform has been previously approved in the US, Australia, and Singapore.
Dr. Murphy on increasing diversity in cancer clinical trials
February 29th 2024

Dr. Murphy on increasing diversity in cancer clinical trials

Urology Times staff
In this podcast episode, Adam B. Murphy, MD, MBA, MSCI, discusses the need to increase diversity in clinical trials, specifically focusing on studies in prostate cancer.
Dual-masked PSMA-targeting T-cell engager shows promise in mCRPC
January 9th 2025

Dual-masked PSMA-targeting T-cell engager shows promise in mCRPC

Hannah Clarke
Following an initial dose of VIR-5500 of 120 µg/kg or higher, all patients achieved a PSA reduction.
Expanded indication sought for darolutamide in mHSPC in China
January 7th 2025

Expanded indication sought for darolutamide in mHSPC in China

Hannah Clarke
The application is supported by data from the pivotal phase 3 ARANOTE trial.
© 2025 MJH Life Sciences

All rights reserved.